Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541654 · ClinicalTrials.gov registry record
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
A clinical trial of Li-Fraumeni Syndrome and Hereditary Cancer Syndrome, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 3
- Study locations
NCT04541654 is a study of Li-Fraumeni Syndrome and Hereditary Cancer Syndrome that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,500 participants, below the 1,826-participant average among 6 other Li-Fraumeni Syndrome trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04541654, a study of Li-Fraumeni Syndrome and Hereditary Cancer Syndrome, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Conditions Studied
Interventions
- GENETIC Data and Specimen Collection
Study Locations (3)
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
- Judy E. Garber - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541654
The ClinicalTrials.gov registry entry for NCT04541654 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,826-participant average among 6 other Li-Fraumeni Syndrome trials with a reported enrollment target (18% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Li-Fraumeni Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Data and Specimen Collection is the first listed.
NCT04541654 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04541654 about?
NCT04541654 is a clinical study titled "Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress". The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
What is the current status of trial NCT04541654?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2020-09-15. Estimated completion is 2025-12-31.
What conditions does trial NCT04541654 study?
This clinical trial studies the following conditions: Li-Fraumeni Syndrome, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism, TP53 Gene Mutation.
What interventions are being tested in trial NCT04541654?
The interventions under investigation include: Data and Specimen Collection (GENETIC).
Who is sponsoring clinical trial NCT04541654?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04541654 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Li-Fraumeni Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Clinical and Genetic Studies of Li-Fraumeni Syndrome
RECRUITING
-
Li-Fraumeni Syndrome/TP53 Biobank
RECRUITING
-
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
RECRUITING
-
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
ACTIVE NOT RECRUITING · NA
-
Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.